$77M Series C Fuels Iterative Health’s Clinical Trial Acceleration Ambitions
Event summary
- $77M Series C led by Intrepid Growth Partners and GV, with new investors EDBI and a family office.
- Global network of over 100 research sites across North America, Europe, India, and Australia.
- 2x faster site activation and 3x higher patient enrollment rates compared to industry benchmarks for IBD trials.
- Expansion into cardiology and obesity therapeutic areas beyond gastroenterology and hepatology.
The big picture
Iterative Health's $77M Series C underscores the growing investment in AI-driven solutions for clinical trial acceleration, a critical bottleneck in drug development. The company's model of embedding research directly into clinical care addresses systemic challenges in trial enrollment and site activation, positioning it as a key player in transforming patient outcomes through faster therapeutic access.
What we're watching
- Therapeutic Expansion
- The pace at which Iterative Health can successfully integrate and scale new therapeutic areas like cardiology and obesity.
- Geographic Growth
- Whether the company's continued geographic expansion will maintain its current enrollment and activation efficiencies.
- AI Integration
- How Iterative Health's proprietary AI technology will evolve to support broader therapeutic areas and larger patient populations.